

Venus Medtech Hosts Inaugural Global Partner Summit in Paris

Descrizione

default watermark

COMUNICATO STAMPA â?? CONTENUTO PROMOZIONALE

Company highlights international growth strategy, expanding structural heart portfolio, and commercialization priorities

PARIS, May 26, 2026 /PRNewswire/ â?? Venus Medtech convened its inaugural Global Partner Summit in Paris under the theme â??Insights, Innovation, Impact,â?• bringing together distributors and commercial partners to discuss the companyâ??s international growth strategy, structural heart portfolio expansion, and long-term commercialization priorities.

The event marked a milestone in Venus Medtechâ??s efforts to strengthen alignment with its global partner network as the company continues to expand its presence across international markets.

Opening the summit, David BrÃ©ant, Vice President of Sales and Marketing at Venus Medtech, reflected on the companyâ??s evolution from an emerging innovator to a growing player in the global structural heart market, emphasizing the importance of clinical collaboration, product quality, and long-term execution.

Hou-Sen Lim, General Manager and CEO of Venus Medtech, outlined the companyâ??s strategic roadmap, highlighting progress across its transcatheter valve portfolio as well as upcoming regulatory and commercial milestones. He said the company is continuing to evolve from a product-focused organization into a multi-platform structural heart company spanning multiple valve therapies.

A featured session led by Prof. Francesco Maisano, Chief of Cardiac Surgery and Director of the Valve Clinic at IRCCS San Raffaele University Hospital, focused on the development of Cardiovalve and the growing demand for transcatheter treatment options for mitral regurgitation (MR) and tricuspid regurgitation (TR).

The presentation highlighted several design features of the Cardiovalve system, including single-step transfemoral access, a unified platform for both mitral and tricuspid procedures, a low-profile design intended to reduce left ventricular outflow tract (LVOT) obstruction risk, and an adaptive sealing

mechanism designed to minimize paravalvular leak (PVL). According to the presentation, current device sizing is expected to address approximately 85% of the target patient population.

The session also underscored increasing clinical and commercial interest in therapies targeting the tricuspid valve, often referred to within the industry as the â??forgotten valveâ?• due to historically limited treatment options.

â??International expansion remains a core strategic priority for Venus Medtech,â?• said Hou-Sen Lim. â??Following the international commercialization of Venus P-Valve, we are advancing the clinical, regulatory, and commercialization pathways for Venus-PowerX, Venus-Vitae, and Cardiovalve. We remain focused on building long-term clinical credibility and strengthening our presence in the global structural heart market through a broader and increasingly diversified product portfolio.â?•

He added that the company continues to invest in local commercial capabilities, service infrastructure, and market-specific expertise to support growth across key international markets.

About Venus Medtech

default watermark

Venus Medtech (Hangzhou) Inc. (2500.HK) develops transcatheter heart valve technologies and treatment solutions for structural heart disease. The companyâ??s pipeline includes products and candidates across transcatheter aortic, pulmonary, mitral, and tricuspid valve therapies, along with related accessory products. Venus Medtech operates research and development centers in China, the United States, and Israel.

View original content:https://www.prnewswire.co.uk/news-releases/venus-medtech-hosts-inaugural-global-partner-summit-in-paris-302781488.html

Copyright 2026 PR Newswire. All Rights Reserved.

COMUNICATO STAMPA â?? CONTENUTO PROMOZIONALE: Immediapress Ã¨ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dallâ??ente che lo emette. Lâ??Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

â??

immediapress/pr-newswire

Categoria

1. Comunicati

Tag

1. ImmediaPress

Data di creazione
Maggio 26, 2026
Autore
redazione